Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based studyResearch in context
Summary: Background: We examined the real-world comparative safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. other newer anti-glycemic medications (dipeptidyl peptidase-4 inhibitors [DPP4i], glucagon-like peptide-1 receptor agonists [GLP1a]) in patients with and without chronic kidne...
Furkejuvvon:
Váldodahkkit: | , , , , , , , , , , |
---|---|
Materiálatiipa: | Girji |
Almmustuhtton: |
Elsevier,
2024-08-01T00:00:00Z.
|
Fáttát: | |
Liŋkkat: | Connect to this object online. |
Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Interneahtta
Connect to this object online.3rd Floor Main Library
Hildobáiki: |
A1234.567 |
---|---|
Njađus 1 | Oažžumis |